(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
1.83% $ 2.23
Live Chart Being Loaded With Signals
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use...
Stats | |
---|---|
Volumen de hoy | 4.48M |
Volumen promedio | 599 679 |
Capitalización de mercado | 127.83M |
EPS | $0 ( 2024-03-14 ) |
Próxima fecha de ganancias | ( $0 ) 2024-05-07 |
Last Dividend | $0.667 ( 2014-10-31 ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.01 |
ATR14 | $0.0250 (1.12%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-21 | Baylor-henry Minnie | Sell | 32 800 | Common Stock |
2023-09-21 | Baylor-henry Minnie | Sell | 26 400 | Common Stock |
2023-09-21 | Baylor-henry Minnie | Sell | 12 800 | Stock option (right to buy) |
2023-09-21 | Hoffmann Rolf K | Sell | 64 000 | Common Stock |
2023-09-21 | Hoffmann Rolf K | Sell | 20 000 | Common Stock |
INSIDER POWER |
---|
-64.25 |
Last 96 transactions |
Buy: 1 606 755 | Sell: 5 363 965 |
Volumen Correlación
Paratek Pharmaceuticals Correlación
10 Correlaciones Más Positivas | |
---|---|
PAIC | 0.948 |
SVOK | 0.947 |
BIOL | 0.912 |
RMRM | 0.909 |
YMAB | 0.899 |
SVAC | 0.89 |
AVCT | 0.883 |
TSP | 0.879 |
UK | 0.876 |
GAINL | 0.876 |
10 Correlaciones Más Negativas | |
---|---|
BOCH | -0.954 |
NETE | -0.938 |
MMAC | -0.912 |
RAVN | -0.903 |
SHSP | -0.9 |
LMRK | -0.894 |
QADA | -0.878 |
VLYPO | -0.862 |
AMRB | -0.862 |
PODD | -0.858 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Paratek Pharmaceuticals Correlación - Moneda/Commodity
Paratek Pharmaceuticals Finanzas
Annual | 2022 |
Ingresos: | $150.79M |
Beneficio Bruto: | $127.73M (84.71 %) |
EPS: | $-1.170 |
FY | 2022 |
Ingresos: | $150.79M |
Beneficio Bruto: | $127.73M (84.71 %) |
EPS: | $-1.170 |
FY | 2021 |
Ingresos: | $130.16M |
Beneficio Bruto: | $108.63M (83.46 %) |
EPS: | $-1.201 |
FY | 2020 |
Ingresos: | $46.92M |
Beneficio Bruto: | $38.27M (81.56 %) |
EPS: | $-2.19 |
Financial Reports:
No articles found.
Paratek Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $15.96 | 2014-05-21 |
Last Dividend | $0.667 | 2014-10-31 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 4 | -- |
Total Paid Out | $40.59 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.91 | -- |
Div. Sustainability Score | 0.312 | |
Div.Growth Potential Score | 0.170 | |
Div. Directional Score | 0.241 | -- |
Year | Amount | Yield |
---|---|---|
2014 | $40.59 | 172.60% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.299 | 1.500 | -5.98 | -8.98 | [0 - 0.5] |
returnOnAssetsTTM | -0.287 | 1.200 | -9.57 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.224 | 1.500 | 8.63 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0.519 | 0.800 | -2.40 | -1.923 | [1 - 3] |
quickRatioTTM | 0.420 | 0.800 | -2.23 | -1.786 | [0.8 - 2.5] |
cashRatioTTM | 0.211 | 1.500 | 9.94 | 10.00 | [0.2 - 2] |
debtRatioTTM | 1.782 | -1.500 | 10.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -1.959 | 1.000 | -1.837 | -1.837 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.189 | 2.00 | -0.0628 | -0.126 | [0 - 30] |
freeCashFlowPerShareTTM | -0.190 | 2.00 | -0.0949 | -0.190 | [0 - 20] |
debtEquityRatioTTM | -1.290 | -1.500 | -5.16 | 7.74 | [0 - 2.5] |
grossProfitMarginTTM | 0.850 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.201 | 1.000 | -6.01 | -6.01 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.0416 | 1.000 | -1.342 | -1.342 | [0.2 - 2] |
assetTurnoverTTM | 0.960 | 0.800 | 6.94 | 5.55 | [0.5 - 2] |
Total Score | 0.312 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -3.05 | 1.000 | -0.409 | 0 | [1 - 100] |
returnOnEquityTTM | 0.224 | 2.50 | 9.12 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.190 | 2.00 | -0.0632 | -0.190 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.189 | 2.00 | -0.0628 | -0.126 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.179 | 1.500 | -2.14 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.0772 | 1.000 | -4.43 | 0 | [0.1 - 0.5] |
Total Score | 0.170 |
Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico